AR024463A1 - Agonistas de somatostatina - Google Patents

Agonistas de somatostatina

Info

Publication number
AR024463A1
AR024463A1 ARP000103155A ARP000103155A AR024463A1 AR 024463 A1 AR024463 A1 AR 024463A1 AR P000103155 A ARP000103155 A AR P000103155A AR P000103155 A ARP000103155 A AR P000103155A AR 024463 A1 AR024463 A1 AR 024463A1
Authority
AR
Argentina
Prior art keywords
trp
cys
group
tyr
alkyl
Prior art date
Application number
ARP000103155A
Other languages
English (en)
Original Assignee
Scient S C R A S Soc De Conseils De Rech S Et D Applic S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scient S C R A S Soc De Conseils De Rech S Et D Applic S filed Critical Scient S C R A S Soc De Conseils De Rech S Et D Applic S
Publication of AR024463A1 publication Critical patent/AR024463A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C07K14/6555—Somatostatins at least 1 amino acid in D-form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)

Abstract

Se refiere a péptidos cíclicos de formula (1): X-A1-ciclo(D-Cys-A3-A4-Lys-A6-A7)-A8-Y o su sal farmacéuticamente aceptable, en donde: X es H, formula (2) oformula (3); A1 y A3 son cada uno independientemente el isomero D- o L- de un aminoácidoselecc ionado entre el grupo que consiste en Phe, Tyr, Tyr(I), Trp,3-Pal, 4-Pal, Cpa y NaI; A4 es L-Trp, D-Trp, L-beta-metil-Trp o D-beta-metil-Trp; A6 es -NH-(CHR1)n-CO-, donde n es 2, 3 o 4; A7 es L- o D-Cys; A8 es elisomero D o L de un aminoácidoselecci onado entre el grupo que consiste en Phe, Tyr, Tyr(I), Trp, NaI, Cpa, Val, Leu, IIe, Ser y Thr; Y es NR2R3 donde R2 y R3son cada uno independientemente H o alquilo C1-5; R1 se selecciona entre el grupo que consiste en H, alquilo C1-4 y-CH2-arilo; en donde dicho arilo es unaporcion optativamente sustituida seleccionada entre el grupo que consiste en fenilo, 1-naftilo y 2-naftilo, en donde dicha porcion optativamente sustituida esoptativamente sustituida con uno o más sustituyentescada uno selec cionado independientemente entre el grupo que consiste en alquiloC1-6, alquenilo C2-6,alquinilo C2-6, arilo, arilalquilo C1-6, alcoxi C1-6, -N(R4R5), -COOH, -CON(R4R5), halo, -OH, -CN, y -NO2; R4 y R5 cada uno es, independientementepara cadaaparicio n, H o alquilo C1-3; donde el Cys de A2 está unido al Cys de A7 por un enlace di-sulfuro formado de los grupos tiol de cada Cys; composicionesfarmacéuticas que comprenden dichos péptidos y el uso de las mismas como un agonista delos subtipos del rec eptor de somatostatina. Los péptidos de la presentese unen selectivamente al tipo 5 del receptor de los subtipos de somatostatina y producen un efecto agonista de los receptores de subtipo de somatostatina alas cuales se unenlos péptidos.
ARP000103155A 1999-06-25 2000-06-23 Agonistas de somatostatina AR024463A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14102899P 1999-06-25 1999-06-25

Publications (1)

Publication Number Publication Date
AR024463A1 true AR024463A1 (es) 2002-10-02

Family

ID=22493842

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000103155A AR024463A1 (es) 1999-06-25 2000-06-23 Agonistas de somatostatina

Country Status (14)

Country Link
EP (1) EP1189942A1 (es)
JP (1) JP4041311B2 (es)
CN (1) CN1367792A (es)
AR (1) AR024463A1 (es)
AU (1) AU770958B2 (es)
BR (1) BR0011919A (es)
CA (1) CA2377265A1 (es)
CZ (1) CZ20014534A3 (es)
HU (1) HUP0201696A3 (es)
IL (1) IL146941A0 (es)
MX (1) MXPA01013127A (es)
PL (1) PL352763A1 (es)
RU (1) RU2263677C2 (es)
WO (1) WO2001000676A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4294959B2 (ja) 2001-03-06 2009-07-15 ウニベルシタ・デグリ・ストゥッディ・ディ・フェラーラ 髄様甲状腺癌の増殖を変調させる方法
US7189856B2 (en) 2001-12-28 2007-03-13 Gideon Shapiro Non-peptide somatostatin receptor ligands
EP2527008A3 (en) * 2007-04-30 2013-01-16 Technion Research & Development Foundation Ltd. Anticancerous polymeric agents
EP2152289A1 (en) 2007-04-30 2010-02-17 Technion Research & Development Foundation Ltd. Novel antimicrobial agents
WO2011063366A1 (en) * 2009-11-23 2011-05-26 Palatin Technologies, Inc. Melanocortin-1 receptor-specific cyclic peptides
WO2011151782A1 (en) 2010-06-02 2011-12-08 Preglem Sa A role for somatostatin to modulate initiation of follicular growth in the human ovary
WO2013119800A1 (en) 2012-02-07 2013-08-15 Massachusetts Institute Of Technology Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness
US9724396B2 (en) 2013-03-15 2017-08-08 Massachusetts Institute Of Technology Use of antagonists of growth hormone or growth hormone receptor to prevent or treat stress-sensitive psychiatric illness
WO2016138099A1 (en) 2015-02-24 2016-09-01 Massachusetts Institute Of Technology Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0083305B1 (de) * 1981-12-24 1985-07-10 Ciba-Geigy Ag Cyclische Octapeptide und pharmazeutische Präparate davon, sowie Verfahren zur Herstellung derselben und ihre Anwendung
HU207104B (en) * 1991-01-25 1993-03-01 Biosignal Kutato Fejlesztoe Kf Process for producing new somatostatin analogs inhibiting tumour growth and pharmaceutical compositions comprising such compounds
EP1288223B1 (en) * 1993-08-09 2004-12-08 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Therapeutic peptide derivatives
AU728224B2 (en) * 1996-12-04 2001-01-04 Administration Of The Tulane Educational Fund, The Somatostatin antagonists
WO1998050063A1 (en) * 1997-05-01 1998-11-12 Cedars-Sinai Medical Center Method of treating hyperprolactinemia and prolactinomas
DK0981363T3 (da) * 1997-05-13 2003-12-01 Sod Conseils Rech Applic Somatostatinagonister til reduktion af legemsvægt
WO1998051330A1 (en) * 1997-05-13 1998-11-19 Societe De Conseils De Recherches Et D'applications Scientifiques S.A. (S.C.R.A.S.) Method and compositions for treating hyperlipidemia and other conditions
CA2289499C (en) * 1997-05-13 2010-02-23 Michael Anthony Cawthorne Somatostatin and somatostatin agonists for treating insulin insensitivity and syndrome x

Also Published As

Publication number Publication date
RU2263677C2 (ru) 2005-11-10
IL146941A0 (en) 2002-08-14
EP1189942A1 (en) 2002-03-27
WO2001000676A1 (en) 2001-01-04
CA2377265A1 (en) 2001-01-04
JP2003503369A (ja) 2003-01-28
AU770958B2 (en) 2004-03-11
HUP0201696A2 (en) 2002-09-28
HUP0201696A3 (en) 2002-10-28
AU6200000A (en) 2001-01-31
JP4041311B2 (ja) 2008-01-30
PL352763A1 (en) 2003-09-08
CN1367792A (zh) 2002-09-04
MXPA01013127A (es) 2002-11-04
BR0011919A (pt) 2002-03-19
CZ20014534A3 (cs) 2002-06-12

Similar Documents

Publication Publication Date Title
AR024463A1 (es) Agonistas de somatostatina
TR200200252T2 (tr) Şimerik polipeptidler, bunların üretimi için yöntem ve kullanımı
TR199902997T2 (xx) "LH-RH peptit analoglar�, bunlar�n kullan�mlar� ve bunlar� i�eren farmas�tik terkipler"
CA2060034A1 (en) Tumour growth-inhibiting somatostatin analogues, pharmaceutical compositions containing them and process for preparing same
TR199901028T2 (xx) Heptapeptid oksitosin analoglar�.
RU2014137107A (ru) Пептидомиметические макроциклы
LV5794A4 (lv) Nonapeptidi ar bombezina antagonistu ipasibam
UY27109A1 (es) Derivados de quinazolona como antagonistas de receptores adrenergicos alfa-1a/b
DK200100558A (da) Anvendelse af en somatostatinanlæg til fremstilling af et lægemiddel til behandling af bryskræft
AR048949A1 (es) Camptotecina conjugada en posicion 7 con antagonistas de la integrina
ES2090143T3 (es) Acidos gem-difosfonicos, un procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
RU2002101732A (ru) Агонисты соматостатина
NZ335879A (en) Somatostatin antagonist peptides having a D-amino acid at the second residue
KR930017887A (ko) 약제학적 화합물
AR044852A1 (es) Una composicion farmaceutica para la administracion parenteral que comprende un analogo de somatostatina
DE3863560D1 (de) Peptidderivate von cck8, deren herstellung und sie enthaltende pharmazeutische zusammensetzungen.
AR026068A1 (es) Peptidos modificados y peptidomimeticos para el uso en inmunoterapia.
ES2191922T3 (es) Nuevos derivados de amida y sus composiciones medicinales.
GB1435384A (en) Psychopharmacologically active peptides
BR112022003359A2 (pt) Composição de amida peptídica e método de preparação da mesma
GB1425099A (en) Psychopharmacologically active peptides
AR004497A1 (es) Un análogo hexapéptido cíclico de somatostatina, procedimiento para prepararlos y las composiciones farmacéuticas que los contienen y el uso de dicho hexapéptido para la preparación de una composición farmacéutica.
AR006926A1 (es) Analogos hidrosolubles del anillo c de 20(s)-camptotecina, composicion farmaceutica, su uso para preparar medicamentos y procesos para su preparacion
AR116636A1 (es) Radiofármacos dirigidos a grpr y usos de los mismos
RU2021103167A (ru) Пептидные соединения и их терапевтическое применение

Legal Events

Date Code Title Description
FB Suspension of granting procedure